A Nationwide Analysis of the Impact of Vasculopathies on COVID-19 Hospitalization Outcomes

Résumé

Abstract Background and Aims: The study investigated the short-term outcomes of COVID-19 in conjunction with vasculopathies, including vasculitides, for inpatient hospitalization encounters. Methods: The 2020 National Inpatient Sample was used to identify hospitalizations presenting with a primary admitting diagnosis of COVID-19 with and without a secondary diagnosis of vasculopathy, including vasculitides. The primary outcomes of interest were mortality and mechanical ventilation use in COVID-19 hospitalizations with and without vasculopathies. Secondary outcomes were in-hospital length of stay and hospital charges. Results: A total of 1,050,040 weighted hospitalizations were included in this study with a principal diagnosis of COVID-19. Among this population, 1,440 weighted hospitalizations had a concurrent diagnosis of vasculopathy, and 1,048,600 weighted hospitalizations had COVID-19 without a concurrent diagnosis of vasculopathy. Positive associations regarding mortality were found in Kawasaki disease (aOR 7.9115, 95% CI [1.4612 - 42.8362]; p = 0.0164), microscopic polyangiitis (aOR 3.5589, 95% CI [1.1356 - 11.1529]; p = 0.0295), thrombotic microangiopathy (aOR 3.9213, 95% CI [2.1959 - 7.0027]; p = 4.00E-06), other specified necrotizing vasculitis (aOR 20.9423, 95% CI [4.5566 - 96.2510]; p = 9.44E-05), unspecified necrotizing vasculopathy (aOR 16.6108 , 95% CI [2.0106 - 137.2299]; p = 0.0091), and cryoglobulinemia (aOR 8.5863 , 95% CI [2.2848 - 32.2669]; p = 0.0015). Positive associations regarding mechanical ventilation were found in microscopic polyangiitis (aOR 7.4010, 95% CI [2.9088 - 18.8311]; p = 2.72E-05), thrombotic microangiopathy (aOR 3.5112, 95% CI [2.1457 - 5.7459]; p = 6.06E-07), other specified necrotizing vasculitis (aOR 34.9851, 95% CI [6.5912 - 185.6968]; p = 3.06E-05), and unspecified necrotizing vasculopathy (aOR 18.3357, 95% CI [2.2010 - 152.7467]; p = 0.0072). Additionally, the relative difference in length of stay was 53% higher in COVID-19 hospitalizations with vasculopathies than those without (RD 1.53, 95% CI [1.35 - 1.74]; p = 6.18E-11); similarly, the relative difference in total hospital charges was 97% higher (RD 1.97, 95% CI [1.58 - 2.46]; p = 2.18E-09). Conclusion: This study demonstrates significantly higher odds of morbidity and mortality among COVID-19 hospitalizations with vasculopathies substantiating previous claims in the literature.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0